Levosimendan - AbbVie/Tenax Therapeutics

Drug Profile

Levosimendan - AbbVie/Tenax Therapeutics

Alternative Names: Daxim; ODM 109; OR-1259; Simdax

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orion
  • Developer Abbott Laboratories; AbbVie; Imperial College of Science, Technology and Medicine; Orion; Tenax Therapeutics
  • Class Antiarrhythmics; Cardiotonics; Cardiovascular therapies; Hydrazones; Nitriles; Pyridazines; Small molecules; Vasodilators
  • Mechanism of Action Calcium-binding protein modulators; Calcium-sensitising phosphodiesterase inhibitors; Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Phase III Amyotrophic lateral sclerosis; Low cardiac output
  • Discontinued Chronic heart failure; Myocardial infarction; Septic shock; Stroke; Transient ischaemic attacks

Most Recent Events

  • 21 Jun 2018 Phase-III clinical trials in Amyotrophic lateral sclerosis in USA, Sweden, Spain, Belgium (PO) (NCT03505021)
  • 13 Jun 2018 Yooyoung Pharmaceutical plans a phase III trial for Acute heart failure in South Korea (NCT03555123)
  • 01 Jun 2018 Tenax Therapeutics plans the phase II PH-HFpEF trial for Pulmonary hypertension in USA, in the third quarter of 2018 (NCT03541603)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top